Actavis Generics

T2 Biosystems and Bayer AG have entered a multi-year research and development (R&D) agreement to further research on the T2 Magnetic Resonance technology (T2MR) with haemostasis drug discovery.

According to the agreement, Bayer’s will combine its R&D efforts with T2 Biosystems’ T2 magnetic resonance technology platform (T2MR), to develop tools and evaluate assays to promote drug discovery and biomarker research for haemostasis-related programmes.

Celgene Corporation has signed a co-development agreement with Jounce Therapeutics for developing novel immuno-oncology therapies to bring about transformation in cancer treatments.

Pursuant to the agreement, Celgene will be responsible to develop Jounce Therapeutics’ lead product candidate JTX-2011, while Jounce Therapeutics will receive an upfront payment of $225m and a $36m equity investment from Celgene.

Jounce Therapeutics will be responsible for the global development and US commercialisation of JTX-2011.

The partnership enables the two companies to further advance discovery and development of next-generation immune-therapies for cancer patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Teva Pharmaceuticals plans to raise gross proceeds of $3.5bn through the public offering of 3.15% of its senior notes,  due on 1 October 2026. The offering is expected to be completed by 21 July 2016.

The company plans to use the proceeds for the acquisition of Actavis Generics, and to finance its ADSs warrants, debt securities, depositary shares and units.

Oncorus INC. plans to advance its immunotherapy platform using oncolytic herpes simplex virus (oHSV) through the funds raised from a series A financing round.

"The partnership enables the two companies to further advance discovery and development of next-generation immune-therapies for cancer patients."

The company has raised $57m through the financing round, which was led by MPM Capital, L.P. and co-led by Deerfield Management Company LP, Arkin Bio Ventures, Celgene INC, Excelyrate Capital, Long March Investment Fund, and SunStates Fund, LP.

Teva Pharmaceuticals has priced the public offering of of its 2.8% senior notes due 21 July 2023. The company expects to raise gross proceeds of $3bn through the offering.

Rothschild & Co. is acting as the financial advisor and Willkie Farr & Gallagher LLP, Tulchinsky Stern Marciano Cohen Levitski & Co and Van Doorne N.V are acting as legal advisors for the offering.

The company plans to invest the funds in the acquisition of Actavis Generics and for other general corporate purposes.

Image: Teva Pharmaceuticals plans to acquire Actavis Generics. Photo: Courtesy of Johann Heioar Arnason.